MDGL - Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer | Benzinga
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer.
Ms. Dier has spent more than 20 years in executive financial leadership roles in the biopharmaceutical industry, with deep experience in operational and strategic decision making, capital raising, financial planning and accounting (FP&A), global supply chain management, investor relations and business development. She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc.
Bill Sibold, Chief Executive Officer of Madrigal, stated, "Mardi has an outstanding track record of experience helping biopharmaceutical companies scale for commercial success, and her diverse operational and strategic capabilities make her an ideal addition to the leadership team as Madrigal enters its next phase of expansion and growth."
"I am thrilled to be joining the Madrigal team as the Company ramps up for the launch of resmetirom and continues to build a more fully integrated organization that will lead the way in NASH for years to come," said Ms. Dier. "Madrigal has a unique opportunity to transform care for patients and become the next major ...